Lercanidipina Ratiopharm

Lercanidipine hydrochloride, the active ingredient in Lercanidipina Ratiopharm, is a calcium channel blocker presented as a tablet for oral use. It works by relaxing vascular smooth muscle, thereby lowering blood pressure and is indicated for the management of hypertension in adult patients.

GNH USA supplies Lercanidipina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets with adherence to stringent quality standards.

Lercanidipine, a dihydropyridine calcium channel blocker, is employed in the therapeutic management of elevated blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. Isolated systolic hypertension: lowers systolic pressure in patients with predominant systolic elevation. Essential hypertension: provides long‑term control of primary high blood pressure.

Lercanidipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe hypotension - Angioedema - Myocardial infarction - Hepatic dysfunction

When prescribing lercanidipine, clinicians should consider several safety measures.

Blood pressure monitoring: regularly assess to avoid excessive hypotension. Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction. Concomitant antihypertensives: evaluate risk of additive blood pressure lowering. Elderly patients: start at low dose and monitor for dizziness or falls. Store at room temperature: keep in original packaging, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can markedly raise drug concentration. - Other calcium channel blockers: additive vasodilatory effect leading to hypotension. - Anti‑arrhythmic agents (e.g., diltiazem): risk of severe bradycardia. - Concurrent use with other antihypertensives at high doses: risk of excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: monitor for combined heart rate reduction. - NSAIDs: may blunt antihypertensive response. - Alcohol: can increase dizziness and hypotensive effect.